Good Ventures awarded a grant of $500,000 to the Multidisciplinary Association for Psychedelic Studies (MAPS) to support a randomized controlled trial testing the use of MDMA-assisted psychotherapy to treat posttraumatic stress disorder. See MAPS’ budget and budget guide for more information on the project.
Research on psychedelics appears to be a neglected and potentially important aspect of drug policy reform, and it’s our impression that MAPS is one of the leading nonprofits undertaking research on possible medical uses for psychedelics. This grant is part of our work on drug policy reform.